CARE ACROSS LTD

Their core work

Care Across is a London-based health technology SME that applies artificial intelligence and big data analytics to improve patient outcomes, with a strong focus on cancer care. They develop data-driven tools that help predict health trajectories, monitor wellbeing, and support clinical decision-making for cancer patients during and after treatment. Their work bridges the gap between large-scale health data collection and actionable insights for healthcare providers and patients alike.

What they specialise in

How they've shifted over time

Care Across began with broader public health data work through CrowdHEALTH (2017), focused on aggregating population-level health information for policy support. By 2020, they had narrowed sharply toward cancer-specific AI applications, launching two concurrent projects (ONCORELIEF and ASCAPE) centered on machine learning for cancer patient wellbeing and care prediction. This trajectory shows a clear specialization from general health informatics toward precision oncology support tools.

Care Across is deepening its specialization in AI-powered oncology support, making them a strong candidate for future projects combining machine learning with cancer survivorship or personalized treatment monitoring.

How they like to work

Care Across operates exclusively as a consortium partner, never as coordinator, which suggests they bring specialized technical capability rather than project management leadership. With 49 unique partners across just 3 projects, they work in large research consortia — averaging over 16 partners per project. This indicates comfort operating in complex, multi-national teams where they contribute a defined technical component.

Despite only three projects, Care Across has built a broad network spanning 49 unique partners across 16 countries, reflecting the large consortium sizes typical of EU health research. Their reach is firmly pan-European with no obvious geographic concentration.

What sets them apart

Care Across occupies a niche at the intersection of AI, big data, and oncology patient support — a combination few SMEs can credibly claim with EU project backing. As a private company rather than a research institute, they are positioned to translate research outputs into deployable products and services. For consortium builders, they offer a rare combination: SME agility, health AI expertise, and proven experience in large EU health projects.

Highlights from their portfolio

• ASCAPE
  Largest funding (€408K) and most technically ambitious — combines AI, machine learning, big data analytics, and health economics to support cancer patients across Europe.
• ONCORELIEF
  Highest single funding (€419K) with a distinctive 'digital guardian angel' concept for post-treatment cancer patient monitoring and wellbeing.